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Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its
frequency and severity, prevention of pertussis has been considered an important public
health issue for many years. The development of the whole-cell pertussis vaccine (wPV)
and its introduction into the pediatric immunization schedule was associated with a
marked reduction in pertussis cases in the vaccinated cohort. However, due to the
frequency of local and systemic adverse events after immunization with wPV, work on
a less reactive vaccine was undertaken based on isolated B. pertussis components
that induced protective immune responses with fewer local and systemic reactions.
These component vaccines were termed acellular vaccines and contained one or more
pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA),
pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up
to five components were developed, and several efficacy trials clearly demonstrated that
the aPVs were able to confer comparable short-term protection than the most effective
wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis
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observed in recent years. This paper reports the results of a Consensus Conference
organized by the World Association for Infectious Disease and Immunological Disorders
(WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important
reasons for the pertussis resurgence and the role of different aPVs in this resurgence.
Keywords: acellular pertussis vaccine, Bordetella pertussis, pertussis, whole-cell pertussis vaccine, pertussis
prevention
INTRODUCTION
Pertussis is an acute respiratory disease caused by Bordetella
pertussis, a Gram-negative bacterial pathogen (1). Before the
availability of vaccines, pertussis was a frequent cause of
morbidity and mortality, particularly in infants and young
children. The introduction of pertussis-containing vaccines
into the immunization schedule of infants and children has
reduced pertussis incidence, although sporadic outbreaks remain
relatively common. In a recent publication (2), it was projected
that in 2014, 24. One million cases of pertussis occurred around
the world in children aged <5 years with ∼160,000 deaths and
many hospitalization admissions, some to pediatric intensive care
units. Due to its frequency and severity, pertussis prevention
has been considered an important public health issue for many
years. The development of the whole-cell pertussis vaccine
(wPV) and its introduction into the pediatric immunization
schedule was associated with a marked reduction in pertussis
cases in the vaccinated cohort (3). With widespread use of wPV,
reporting of pertussis declined significantly worldwide, and both
hospitalization rates and deaths due to pertussis were greatly
reduced. However, due to the frequency of local and systemic
adverse events after immunization with wPV, many parents
were refusing vaccination for their children and lawsuits against
the vaccine manufacturers were forcing many of them to stop
producing the vaccine (4–6). Currently, wPV is no longer being
used in most developed countries, but remains in use in most low
and middle income countries (LMIC) (4, 7–9).
Work on a less reactive vaccine was undertaken based on
the isolation of B. pertussis components that induced protective
immune responses with fewer local and systemic reactions. These
component vaccines were termed acellular vaccines and were
composed of one or more pertussis antigens, including pertussis
toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN),
and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations
containing up to five components were developed, and several
efficacy trials clearly demonstrated that the aPVs were able to
confer comparable short-term protection to the most effective
wPVs with fewer local and systemic reactions (10–15) (Figure 1).
With this enhanced safety profile and despite being more
expensive than wPVs, aPVs were included in the pediatric
immunization schedules of many countries, particularly in the
industrialized world (16, 17). After over a decade of use, a rise
in pertussis incidence was demonstrated in several industrialized
countries, including Australia and the United States (18–22).
Some of this apparent increase may also be due to improved
diagnostic methods, such as the use of molecular techniques to
diagnose pertussis, but most experts think that it is also a result
of more rapid waning of immunity after immunization with the
acellular vaccines. Data from the United States document that
4,000 cases were reported annually in the 1980s, but increases to
25,827, 25,616, 27,500, and 48,277 cases were reported in 2004,
2005, 2010, and 2012, respectively (19–21). In 2016, 17,972 cases
were reported, with an incidence rate of 70.9 per 100,000 in
children <6 months, 31.9 per 100 000 in 6 to 11 month-olds,
and 13.7, 14.8, and 16.3 for those aged 1–6, 7–10, and 11–19
years, respectively (23). However, the under-reporting of mild
cases would be lower these rates.
Trends that are not substantially different have been registered
in other areas. In Europe, 48,446 pertussis cases were reported
to the European Surveillance System by 30 EU/EEA countries in
2016. This number was slightly higher than that reported in 2012
(42,572), the year of peak pertussis incidence in Europe. As in the
USA, rates were higher among children <1 year. In this younger
group, the notification rate was 73.6 cases per 100,000 population,
a value significantly higher than that reported in 2014 (51.6 per
100,000 population). Moreover, children between 10 and 14 years
of age were reported to have the second highest incidence rates of
pertussis,∼30 cases per 100,000 population (24).
The reasons for pertussis resurgence have been investigated,
and several possibilities have been considered. This paper reports
the results of a Consensus Conference organized by the World
Association for Infectious Disease and Immunological Disorders
(WAidid) on June 22, 2018, in Perugia, Italy, with the goal
of evaluating the most important reasons for the pertussis
resurgence and the role of different aPVs in this resurgence.
LABORATORY METHODS FOR PERTUSSIS
DIAGNOSIS
Several reports indicate that resurgence of pertussis might
be due, at least in part, to an artifact, resulting from
an incomplete identification of pertussis cases in the past
(Figure 2). The sole use of cultures to confirm B. pertussis
infection has contributed to this phenomenon. Although the
culture method has 100% specificity, its sensitivity is very low
(25). Moreover, nasopharyngeal samples for culture have to
be collected within the first 15 days of the disease, when
symptoms are frequently non-specific, and such a diagnosis is
rarely suspected. Furthermore, isolation can become difficult
if the patient has recently been treated with antibiotics that
are active against B. pertussis (26). In addition, pertussis
cases occurring outside the first year of age (including in
adulthood) frequently present as only prolonged cough and are
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FIGURE 1 | Efficacy of pertussis vaccines against World Health Organization-defined typical pertussis.
FIGURE 2 | Reasons for underestimation of pertussis incidence and mortality.
undiagnosed, resulting in an underestimation of the true disease
incidence (25, 26).
In recent years, more attention has been given to the
epidemiology of pertussis disease in all age groups. New criteria
for the clinical definition of pertussis according to age have
been suggested (27). The enhanced identification of pertussis
cases using molecular methods, particularly in adolescents
and adults, has increased the total number of reported cases
significantly (28). The molecular techniques, particularly real-
time-polymerase chain reaction (RT-PCR), are widely available
in clinical practice and can be completed in a few hours, allowing
rapid diagnosis of pertussis. Moreover, since the techniques do
not require viable bacteria, they are more sensitive (70–99%
vs. 12–60%). However, similar to culture, they are maximally
sensitive during the first 2–3 weeks of disease (29). Finally, to
confirm B. pertussis infection beyond this period in previously
undiagnosed patients, serologic methods detecting anti-pertussis
toxin IgG in serum and saliva have been developed and
validated (30).
The availability of reliable tests for pertussis diagnosis to
physicians was rapidly associated with a relevant increase in
their use and in the number of pertussis cases being reported.
In Australia, the use of both both PCR and serology in patients
with pertussis-like symptoms increased from 0.5% in the period
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from April 2000 to March 2004 to 1.7% in the period between
March 2010 and March 2011. At the same time in Australia,
the proportion of pertussis notifications with a PCR-confirmed
diagnosis increased from 16.3% in the period from April 2000
to March 2004 to 65.3% in the period between April 2010 and
March 2011 (31). In Canada, the availability of a more sensitive
PCR assay was associated with a concomitant 6-fold increase
in specimen submissions and a 5-fold increase in pertussis
incidence (32).
Assessing the impact of the enhanced diagnostic methods
to the resurgence of disease is difficult, given the periodicity
of naturally occurring pertussis, the different control measures
and reporting standards for different countries, and the different
vaccines and schedules recommended in each country. However,
a study carried out by a working group of the WHO seems
to indicate that although improved diagnosis may play a role,
a real increase in pertussis incidence has occurred in recent
years (33). The group prepared a questionnaire to obtain
information on pertussis incidence, vaccination coverage and
schedules, surveillance methods, case definitions, and the type
of vaccine used. The questionnaire was widely distributed to
countries thought to have achieved long-standing high vaccine
coverage and effective disease control. Resurgence was defined
as evidence of a burden of disease higher than that expected
when compared to previous reporting cycles in the same setting.
A total of 19 countries participated. Although the increased
pertussis incidence could be ascribed to cyclic patterns amplified
by detection bias in most of these countries, in five of them
(Australia, Chile, Portugal, USA, and UK), the presence of a true
resurgence of pertussis in recent years was clearly demonstrated.
Only one country using a wPV, Chile, reported a resurgence.
However, this resurgence was mainly ascribed to decreased of
vaccine coverage, variable coverage within the various districts,
changes in the surveillance practices, and problems with the
specificity of diagnostic tests. The WHO group concluded that
pertussis resurgence was not observed in any country using
wPVs, suggesting that a link between aPV use and increased
pertussis reporting existed (33).
REASONS FOR PERTUSSIS RESURGENCE
AFTER ACELLULAR PERTUSSIS VACCINE
INTRODUCTION
Waning of Immunity
As is the case with immunization, natural B. pertussis infection
does not assure permanent protection against pertussis. Several
studies have documented that a second episode of pertussis
can occur some years after the first one. Current estimates
of the duration of protection due to natural infection range
from 7 to 10 years (34, 35) to 20 years (36), but there is
evidence that it can be as short as 3.5 years (37). Differences
may be due to methods used to evaluate protection and
pertussis epidemiology in different countries. However, duration
of protection due to natural B. pertussis infection can vary
from subject to subject as evidenced by Wearing and Rohani
(38) who, exploring the inter-epidemic period and fade-out-
frequency with a mathematical model, concluded that more
than 10% of individuals lose protection within 10 years
from infection whereas others are protected for more than
30 years.
A similar or only slightly reduced duration of protection has
been calculated after immunization with wPV. Lambert (39)
studied a pertussis outbreak that occurred in 1962 in Kent
County, Michigan, USA. He found that the incidence of pertussis
in vaccinated persons was directly related to the interval since
the last immunization with wPV. Among the 210 vaccinated
individuals with pertussis, attack rates were 21, 47, and 65% in
groups of people who had received the vaccine within the last 4,
4 to 7 years earlier and 8–11 years earlier, respectively. Jenkinson
(40) conducted a 10 year study of pertussis in a discrete general
practice community in the UK and reported that protection due
to immunization with wPV was still effective in 85% of children
4 years after immunization, but was reduced to 50% in the
following 3 years.
In contrast, the duration of immunity after immunization
with aPVs appears to be shorter, independent of the schedule
used, the numbers, and concentrations of antigens included in
each vaccine and the methods used to prepare the vaccines.
Reports also suggested that pertussis occurred significantly
earlier in subjects fully vaccinated with aPV than in those
given wPV (41–43). Clark et al. (41) in 2012 reported that
children who were fully immunized during infancy with an
aPV had pertussis more often in the first years of school, while
those given a wPV were at higher risk later, mainly during
adolescence. Similar differences were demonstrated by Vickers
et al. (43), who found that children who had received an aPV
during infancy were already at risk of pertussis within the
first 4 years of life, whereas those vaccinated with wPV did
not contract pertussis until 5–9 years. Finally, Klein et al. (44)
demonstrated that most of the pertussis cases diagnosed in
adolescents during an outbreak were seen in individuals fully
immunized during infancy with an aPV, rather than in those
who had received wPV. Individuals receiving only aPV had
five times higher odds of pertussis disease than those receiving
wPV (OR 5.63, 95% CI 2.55–12.46). When aPV effectiveness
(VE) was measured over time, its effectiveness was lower than
that expected after wPV or natural infection (44). Early waning
of immunity was reported regardless of the schedule used for
immunization (44).
The addition of booster doses of aPV to prolong protection
was also assessed. Although there was transient protection
afforded by additional booster doses, the protection waned
rapidly. A meta-analysis of 11 studies (45) that measured long-
term immunity to pertussis after three or five doses of diphtheria-
tetanus-aP (DTaP), according to the schedules used in many
European countries and in the USA, respectively, did not reveal
a significant difference between the annual odds of pertussis
for the three or five dose regimens. It was calculated that for
every additional year after the last dose of DTaP, the risk of
pertussis increased 1.33 times (95% CI 1.23–1.43), leading to
the conclusion that 8.5 years after the last aPV dose, only 10%
of children were still protected against disease. Similar results
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were reported in another meta-analysis including studies of
aPVs administered according to the USA schedule (46). VE was
compared after the childhood series (five doses) and after an
adolescent booster dose (sixth dose). Relative VE was defined
as VE in the population given prior doses of an aPV and
absolute VE was defined as VE in an aPV-naïve population.
Absolute VE after the childhood series was 91% (95% CI 87–
95%) but declined annually by 9.6% (46). Initial relative VE
after adolescent boosting was 70% (95% CI: 54 to 86%) and
declined by 45.3% annually. The absolute VE of the full six-
dose aPV series was estimated to be 85% (95% CI: 84–86%) in
the first year after series completion. However, it declined by
11.7% (95% CI: 11.1 to 12.3%) per year, and at 18 years of age,
protection was limited to 28.2% of immunized patients (95% CI:
27 to 29%) (46).
Wang et al. (47) studied 279 children aged 5 to 15 years who
presented to primary care with a persistent cough of 2 to 8 weeks
duration. Evidence of recent B. pertussis infection based on a
high oral fluid anti-pertussis toxin IgG titer was demonstrated in
215 children who had been fully vaccinated. Risk was higher in
those who had been immunized ≥7 years earlier, but in 12% of
these cases, chronic cough was demonstrated in patients given an
aPV <7 years before. Further evidence of waning immunity after
recent aPV immunization was reported by Principi et al. (48)
who documented B. pertussis infection in 18.7% (95% CI 11.5–
28.0) of children and adolescents with chronic cough who had
been immunized with an aPV a few years previously (<2 years in
some cases).
Immune Responses to Pertussis Vaccines
and Natural Infection
Studies that have compared immune responses after natural B.
pertussis infection and the administration of both wPVs and aPVs
have clearly shown that the immune stimulation evoked by aPVs
is different from that due to natural infection and wPVs (49–
51). Natural infection evokes bothmucosal and systemic immune
responses, while aPVs induce only a systemic immune response.
As B. pertussis is a mucosal pathogen and only exceptionally
causes infection outside the respiratory tract, this difference is of
particular importance in pertussis control. Mucosal immunity is
essential to prevent colonization and transmission of B. pertussis
organisms. Consequently, preventive measures such as aPVs that
do not induce a valid mucosal response can prevent disease
but cannot avoid infection and transmission. Animal studies
have shown that natural infection is associated with a strong
secretory IgA response in both the upper and lower airways
and induction of resident memory T cells (TRM) (52, 53).
Moreover, it has been recently reported (54) that IL-17 and
IFN-γ-secreting CD69+CD4+ TRM cells were expanded in the
respiratory tract after B. pertussis challenge of mice immunized
with wP, but not aP vaccines. However, natural infection was
associated with the most persistent protection against nasal
colonization and this correlated with potent induction of nasal
tissue TRM cells. These animal data suggest that the lack
of mucosal immune response after aPV administration might
explain its lower efficacy when compared to wPVs and the shorter
duration of protection compared to both wPV vaccination and
natural infection.
Clear differences between systemic immune response after
natural infection and aP and wP vaccines. Natural infection and
wPvs induce antibodies of the IgG1, IgG2, and IgG3 subclasses,
with marginal production of IgG4 (55), suggesting a strong Th1
response. In contrast, the immune response after aPVs evoke a
mixed Th2 and Th17 response (56). APVs evoke the production
of IgG1 and IgG4 antibodies, which is consistent with a Th2
response. Furthermore, aPVs evoke CD4+ T-cells that produce
high concentrations of IL-4 and IL-5 and low amounts of IFNγ,
again consistent with a Th2 response (57).
Since Th1 cytokines play an important role in protection
against pertussis (58, 59), this finding can further explain
the better protection offered by wPVs and natural infection.
Studies carried out in children who have received infant
series of either wPV or aPVs have shown children given
aPVs exhibited higher pertussis-specific antibody levels and
higher memory B- and T-cell responses (5, 60–63). Although
no correlates of antibody protection for pertussis have been
established (64), the higher IgG levels in aPV-immunized
children could lead to the conclusion that better humoral
protection was afforded by the aP rather than wP vaccines.
However, the antigens measured were only those included
in the aPVs and not the additional antigens included in
the wPs.
These differences in immune responses persist over time,
even after booster aPVs (65, 66). The administration of aPV
booster doses at 4 and 9 years of age was associated with an
increase in the production of IgG4, regardless of the type of
vaccine used for priming, but was significantly higher in aPV-
primed children (66). IgG4 antibodies are unable to activate
the complement system and lead to a suboptimal inflammatory
response with impaired phagocytosis and antimicrobial defense,
another potential mechanism for the lower efficacy of aPVs
compared to wPVs (67). Moreover, the evidence that production
of IgG4 after immunization with aPV increases with each
dose seems to indicate that the protection offered by aPVs
tends to be as shorter with each subsequent boosters (68, 69).
Preadolescent booster vaccination with an aPV was found to
induce lower B-cell and Th1 cell responses in aPV-primed
compared with wPV-primed children, resulting in significantly
lower Th1/Th2 ratios. Confirming this, it has been shown that
wPv or aPV primary immunizations in infancy determines
adolescent cellular immune profiles, showing a beneficial Th1-
dominated response after wP-priming (69). These findings
of a preferential Th1 response were also shown in the
baboon model, with aPV vaccines preventing disease after
natural pertussis challenge, but not preventing transmission
of pertussis organisms (70). All these findings indicate that
although aPVs are as individually protective as wPVs in
the first years after priming, they induce shorter long-term
protection than wPVs and a different profile of pertussis-
specific immunity.
Finally, aPV pertussis vaccines do not prevent colonization.
Consequently, they do not reduce the circulation of B.
pertussis and do not exert any herd immunity effect.
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These findings at least partly explain the resurgence
of pertussis.
Genetic Modifications of Bordetella
pertussis
Circulation of B. pertussis strains with modified or absent
antigens included in the aPV have been reported in both the
pre-vaccine era and the aPV era (71–73). Moreover, strains with
polymorphisms of the PT gene resulting in the production of
greater amounts of this protein have been detected (74–79).
Although it cannot be excluded that this phenomenon might
simply be derived from the natural evolutionary course of B.
pertussis, it has been proposed that it might be a consequence of
B. pertussis adaptation to aPV use (80).
Genes encoding antigens included in the aPV vaccines have
evolved at higher rates than other non-vaccine surface protein-
encoding genes soon after the introduction of aPVs into the
pediatric immunization schedule (81). The most compelling data
have been the evolution of PRN-negative B. pertussis strains
according to the use of vaccines PRN-containing vaccines. With
some exceptions (82–84), studies have demonstrated that the
emergence of PRN-deficient strains has resulted as a consequence
of aPV-induced selection pressure. The rate of PRN-negative
isolates is significantly correlated with aPV use in the USA (85).
In Denmark, where an aPV without PRN is used, no PRN-
deficient isolates have been detected (86). In Japan where aPVs
with PRN were administered for many years (87), consistent
rates of PRN-negative strains have been demonstrated over time
(2005–2007, 41%; 2008–2010, 35%; and 2011–2013, 25%) (88,
89). However, when these aPV vaccines were replaced with a
preparation without PRN inNovember 2012, a marked reduction
of PRN-deleted strains was observed (2014–2016, 8%) (90). The
clinical relevance of PRN-deleted strains has not been precisely
defined (80), but children infected with these strains do not
have more severe pertussis (91, 92), In contrast, B. pertussis
strains with the enhanced PT promoter allele PTP3, instead
of the common PTP2 allele, were found to produce greater
amounts of PT (74) and cause more severe disease in younger
infants (92).
Interesting, B. pertussis strains lacking the PRN gene show
increased fitness and/or prolonged infection times in animals
immunized with ACVs (74, 93, 94). This finding suggests that loss
of PRN could lead to a reduced immune response to aPVs and
favor pertussis resurgence. However, clinical studies that have
evaluated the effectiveness of aPVs containing PRN in the setting
of PRN-deficient pertussis have produced conflicting results. One
study in the US (80) assessed the VEs of a five-dose DTaP series
among 4–10 year-olds and a Tdap booster among 11–19 year-
olds in an area where >90% of B. pertussis strains were PRN
deficient. It was found that overall DTaPVEwas 84% (95%CI 58–
94%) while that of TdaP was 70% (95%CI 54–81%), which do not
substantially differ than rates reported during the circulation of
PRN-positive strains. In contrast, a secondUS study revealed that
in vaccinated persons, the likelihood of suffering from pertussis
disease was greater if the infecting strain was PRN-negative than
if it is PRN-positive (85).
In conclusion, aPV use seems to favor adaptation of B.
pertussis strains with emergence of mutated strains. However, the
role of genetic modification in reducing aPV protection remains
unclear with future studies needed.
ROLE OF ANTIGENS INCLUDED IN
PRESENTLY AVAILABLE VACCINES IN
CONDITIONING PROTECTION
Although pertussis resurgence has been demonstrated to be
independent of the type of aPV used, it is theoretically possible
that the composition of vaccines and the immunization strategies
may have played a role in modifying the pertussis incidence.
However, estimates of aPV efficacy and comparisons between
different aPVs are very problematic for several reasons. First,
the criteria for the diagnosis of pertussis used in the various
aPV effectiveness trials have not been uniform. In some cases,
significant underestimations of the real pertussis incidence may
have limited the reliability of final results. When the WHO’s
clinical case definition of pertussis as prolonged paroxysmal
cough is used, it is highly likely that most of the mild cases are
not included. Second, study designs, administration schedules,
and duration of follow-up have not been consistent in the
effectiveness trials. In many European countries, the primary
series includes only two doses of an aPV with a booster dose at
∼1 year. In contrast, in other countries, including the US, the
primary series is based on three doses within the first 6 months
of life, with a booster dose given after the first birthday. Third,
most, but not all, national immunization schedules include a
booster before entering school and during adolescence. Fourth,
the composition of the administered aPV can vary. Most of
these studies have been carried out with vaccines containing
three or five antigens, but in earlier studies vaccines with only
PT have been included. In addition, the quantity of antigen can
differ among the preparations. For example, GSK DTaP vaccines
contain 25 µg PT, 25 µg FHA, and 8 µg PRN, while the Sanofi
preparation also includes FIM2 and three different amounts of
PT, FHA, and PRN for the primary and booster doses. Tdap
contains 10 µg PT, 5 µg FHA, and 3 µg PRN when administered
alone, but when Tdap is combined with polio, hepatitis B, and
Haemophilus influenzae type b, the PT and FHA content is
increased to 20 µg. In addition, the type of aluminum salt used
as an adjuvant and its content vary slightly among between
vaccines. Finally, there has been no single study that directly
compares all aPV vaccines with different numbers and quantities
of included antigens.
Role of the Number of Pertussis Antigens
In those studies that directly compared vaccines using similar
vaccine schedules, similar definitions of pertussis disease, and
comparable durations of follow-up, it can be concluded that the
3-component aPV (3aPV) and the 5-component aPV (5aPV)
have comparable efficacy. Greco et al. evaluated two 3aPVs
produced by different pharmaceutical companies (12), and
Gustafsson et al. (13) studied a 5aPV, with both studies being
conducted in children that had received three doses at∼2, 4, and
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6 months of age and were followed for 2 years. For both 3aPVs,
the overall efficacy was 84% (95% CI 75.8–89.4 for the first and
76.2–89.7 for the second 3aPV), while that of the 5aPV was 85.2%
(95% CI 80.6–88.8) 1 year after first dose (13).
All these vaccines contain PT, which might explain these
relatively similar results. PT seems to be essential for conferring
protection (95, 96). In Sweden (10) and Denmark (97) a vaccine
containing only PT demonstrated effectiveness that did not
differ from that of multivalent aPVs concomitantly used in
other countries. However, lower levels of anti-PT antibodies
have been associated with increased susceptibility to B. pertussis
infection (95, 96). It has not been determined which type and
quantity of PT is able to confer the greatest short- and long-
term protection. Because of its various noxious effects, PT must
be detoxified before inclusion in aPVs. Detoxification can be
achieved genetically or through chemical treatment. The results
of thesemethods are quite different, as genetic detoxification does
not modify the antigenic characteristics of PT and leads to a
protein with superior immunogenicity to chemically detoxified
PT, as clearly demonstrated by an efficacy trial showing that
the PT-9K/129G-based vaccine induces earlier and longer-
lasting protection (98). Additionally, lower doses of genetically
detoxified PT seem to stimulate comparable protection as higher
doses of the chemically detoxified product. In the study by Greco
et al. (12) in which two 3aPVs were evaluated, the protection
offered by the two vaccines was comparable but was achieved
with 5 µg of genetically detoxified PT and with 25 µg of
chemically detoxified PT.
Finally, it cannot be forgotten that not all chemical
treatments have the same impact on PT. Detoxification with
formaldehyde, glutaraldehyde, or with combined procedures are
more destructive of epitopes than detoxification with hydrogen
peroxide, evoking a lower immune response (50). Confirming
this notion, important differences have been evidenced when
comparing two aPVs detoxified by different chemical procedures
in terms of long-term B and T-cell immune responses (99, 100).
The relevance of FHA for inducing protection is less clear.
Several studies in mice suggest that pre-existing serum anti-
FHA antibodies do not protect against pertussis in mice (101).
FHA antibody induced by passive or active immunization did
not protect mice against intracerebral or pulmonary challenge
with B. pertussis (102). Finally, human studies conducted in
Japan suggested that comparable protection was seen after either
an aPV containing PT and FHA or only an aPV including
only PT, although the results of this study remain debatable,
since the PT and FHA combination vaccine contained only
approximately 50% of the PT in PT only product. In contrast,
another study in humans found that the relative efficacy of a
monovalent PT vaccine was significantly less than that seen after
combined PT-FHA vaccine during 3 years of passive surveillance
(103). However, as FHA is an adhesin that is essential for the
adherence of B. pertussis to the respiratory epithelium, it has
been suggested that mucosal antibodies against this antigen
could block adherence, thereby protecting against colonization,
and, consequently, disease (104). This hypothesis is supported
by the evidence that FHA delivered to experimental animals
intranasally can provide protection against aerosol challenge with
B. pertussis (105, 106).
The importance of PRN has already been discussed, and
whether the lack of PRN in the infecting strain can reduce
aPV efficacy remains controversial. Although protection against
pertussis after aPV administration has been correlated with
high serum anti-PRN antibody concentrations, pre-existing PRN
antibodies do not protect against B. pertussis infection (97).
Further studies are in progress to evaluate the impact of
circulating B. pertussis strains lacking pertactin in a systematic
project among EU countries.
Fimbriae are adhesins, and the hypothesis of a potential role
reported previously for FHA can also be suggested for Fim2 and
Fim3. However, data on the potential ability of these antigens
to induce protective mucosal immunity are lacking. Serum
levels of antibodies against Fim2 and Fim3 have been correlated
with protection after household exposure to B. pertussis (107).
Moreover, in a clinical trial, when mild cases of pertussis were
included in the case definition, the efficacy of a 5aPV was found
to be significantly higher than that of a two or three component
aPV. Comparing the relative risk of 3aPV recipients acquiring
pertussis to those receiving 5aPV was 1.82 (95% CI 1.14–2.90),
suggesting a protective role of fimbriae (10, 107). In the presently
available vaccines, FIM2 seems to be more important than FIM
3, as demonstrated by data collected during long-term evaluation
of children included in a study by Olin et al. (108). A slight but
significant reduction in 5aPV efficacy was seen over time when
compared to 3aPV. During that time period, the expression of
fimbriae in circulating B. pertussis changed from predominantly
Fim2 to Fim3; suggesting that the stronger immune responses to
the Fim2 antigen than the Fim3 antigen in the vaccinated subjects
was the cause of the reduced long-term efficacy of the 5aPV,
suggesting that FIM 2 evokesmore relevant protection after 5aPV
administration (109).
VACCINATION COVERAGE AND VACCINE
HESITANCY
Although coverage with one dose of diphtheria- tetanus-pertussis
vaccine (DTP1) is extremely high globally with overall levels
at 90% in 2017, the coverage varies between widely 49 and
99%, depending on the country (110, 111). In 2017, the greatest
number of cases of pertussis were reported in in India (23,766),
Germany (16,183), Australia (12,114), and China (10,390),
countries with national vaccination coverage rates of DTP1 all
above 90% and coverage rates for three doses of DTP (DTP3)
above 88% (112). However, coverage may be high nationally,
there can be regional variation leading to sporadic pertussis cases
and disease outbreaks (111).
Pertussis is an important cause of childhood morbidity
and mortality, especially in infants under 6 months of age.
Maternal pertussis immunization is an effective strategy to
protect infants during this vulnerable period, prior to them being
protected during their childhood vaccination. Maternal pertussis
immunization has been included in national recommendations
across several high-income countries, including the United States
in 2011, the United Kingdom in 2012, and in Australia in 2015
(113, 114). Reasons for non-vaccination in pregnant women are
context specific, and include a lack of awareness, a lack of access,
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a lack of perceived need for the vaccine, and concerns about its
safety and effectiveness (115).
CONCLUSIONS
The resurgence of pertussis observed in recent years seems to
be a complex but real phenomenon resulting from a number of
cases, including the use of aPV in many locales. Lack of mucosal
immune responses after aPV administration favor infection,
persistent colonization, and transmission of the pathogen.
Moreover, earlier waning of protective immunity and the
circulation of B. pertussis variants depleted of vaccine-included
antigens further favor the increase in pertussis disease. Several
different aPVs are available, but it has yet to be determined
which of them confers the highest and the most-prolonged
protection. Further studies are needed to evaluate the importance
of individual antigens included in aPVs in conferring protection
against disease, colonization, and transmission. However, present
knowledge seems to indicate that PT, particularly if genetically
detoxified, represents the main antigen that ensures protection
from disease even if not from infection. The contribution
of FHA, PRN, and FIM2 and FIM3 in vaccine efficacy and
long-lasting protection is still under discussion and needs
further study.
The optimal pertussis vaccine would be one that induced both
a mucosal and systemic responses similar to those occurring
under natural infection, leading to a long-term protection against
both disease and infection. Such a vaccine might increase public
confidence and result in better vaccine uptake. Meanwhile,
the identification of more efficacious vaccination strategies
with currently available vaccines reaching high vaccination
coverage rates is required, including the vaccination of pregnant
women (50).
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